-
Benzinga's Top Pre-Market NASDAQ Gainers (NFLX, SPPI, ZION, GLNG)
Tuesday, March 22, 2011 - 8:10am | 164Benzinga's Top Pre-Market NASDAQ Gainers (NFLX, SPPI, ZION, GLNG) Netflix Inc (NASDAQ: NFLX) rose 3.60% to $220.51 in the pre-market session. NFLX's trailing-twelve-month ROE is 65.75%. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) added 3.03% to $8.15 in the pre-market session. SPPI reported that...
-
China Shenghuo Announces Settlement Agreement for Class Action Lawsuit
Tuesday, March 22, 2011 - 8:04am | 82China Shenghuo Pharmaceutical Holdings, Inc. (NYSE: KUN) announced today the final approval by the court of a settlement agreement resolving and dismissing all claims asserted against the company in the consolidated class action lawsuit, Varghese, et al v. China Shenghuo Pharmaceutical Holdings,...
-
Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO
Tuesday, March 22, 2011 - 8:03am | 71Valeant Pharmaceuticals International, Inc. (NYSE: VRX) today announced the appointment of J. Michael Pearson, currently Valeant's Chief Executive Officer, as Chairman of the Board of Directors, replacing Robert A. Ingram, who remains on the Valeant Board as an independent Board Director and Lead...
-
Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO).
Tuesday, March 22, 2011 - 7:45am | 41Novo-Nordisk's Victoza Approved For Type-2 Diabetes In China (NVO). The Chinese State Food And Drug Administration has approved Novo-Nordisk's (NYSE: NVO) Victoza for Type-2 diabetes treatment.
-
Deutsche Bank Has Buy Rating On Bristol-Myers Squibb (BMY)
Tuesday, March 22, 2011 - 7:41am | 153Deutsche Bank Has Buy Rating On Bristol-Myers Squibb (BMY) Deutsche Bank has a Buy rating and a $31.50 price target on shares of Bristol-Myers Squibb (NYSE: BMY). In a note to investors, Deutsche Bank writes, "BMY issued a brief press release today stating that ipilimumab (ipi) has met the...
-
Discovery Laboratories Reports Q4 Loss of $0.42 per share
Tuesday, March 22, 2011 - 7:11am | 55Discovery Laboratories Reports Q4 Loss of $0.42 per share Discovery Laboratories Inc (NASDAQ: DSCO) reported a Q4 loss at $0.42 per share, versus the expected loss of $0.46 per share. DSCO shares closed at $1.94 yesterday. Read more from Benzinga's Company news.
-
Mylan Announces Exclusive Distribution Partnership with Humeca
Tuesday, March 22, 2011 - 7:05am | 82Mylan Announces Exclusive Distribution Partnership with Humeca Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for...
-
FDA Accepts for Review Spectrum Pharmaceuticals' ZEVALIN Submission for the Removal of the Bioscan
Tuesday, March 22, 2011 - 7:04am | 72FDA Accepts for Review Spectrum Pharmaceuticals' ZEVALIN Submission for the Removal of the Bioscan Spectrum Pharmaceuticals (Nasdaq: SPPI) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the...
-
Stock Market alerts for Tuesday Mar 22
Monday, March 21, 2011 - 5:01pm | 1365( click to enlarge ) Bank of America Corporation (NYSE:BAC) is trapped between the 50 day moving average and the 200 day moving average. I feel a big move one way or the other is coming. A close above the 50 day moving average at $14.31 would be bullish, a close below 200 day moving average...
-
Watson Launches Generic Famvir
Monday, March 21, 2011 - 4:05pm | 95Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Famciclovir tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug...
-
CPEX Advises Stockholders to Vote Today for the All-Cash, Premium FCB Transaction
Monday, March 21, 2011 - 11:56am | 55CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today advised stockholders to vote now FOR the all-cash, premium merger agreement with FCB I Holdings Inc.. Stockholders will receive $27.25 per share if the merger agreement is approved. The special meeting of stockholders to approve the transaction is...
-
Options Brief: XenoPort, Inc. (XNPT)
Monday, March 21, 2011 - 10:20am | 85Shares of XenoPort, Inc. (NASDAQ: XNPT) are lower on the session by 10.94%, trading at $5.94. Overall call volume is now running at 2.52x the daily average, with 36% of all calls traded being purchases on the offer. 3,824 contracts have traded on the session so far. XenoPort, Inc. is a...
-
Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
Monday, March 21, 2011 - 9:51am | 120Attorneys from Dallas' Heygood, Orr & Pearson are announcing a Los Angeles Superior Court ruling that will require executives from Watson Pharmaceuticals Inc. (NYSE: WPI) and its subsidiary companies to testify under oath and produce key documents as part of a lawsuit over the death of a 37-...
-
Goldman Sachs' Position On US Pharma Supported By PFE's New CEO
Monday, March 21, 2011 - 8:39am | 151Goldman Sachs' long-held position that US pharma should get smaller through portfolio rationalizing is further supported by Pfizer Inc.'s (NYSE: PFE) new CEO's announcement to consider breakups or spin-offs of some or all of its business units. “We believe that if PFE were to lead the industry to...
-
Benzinga's Top Pre-Market Losers (S, XNPT, AMT, FSLR)
Monday, March 21, 2011 - 8:24am | 134Sprint Nextel Corporation (NYSE: S) dipped 10.50% to $4.52 in the pre-market session. Google Inc (NASDAQ: GOOG) and Sprint announced plans to integrate their voice services. XenoPort Inc (NASDAQ: XNPT) fell 10.04% to $6 in the pre-market session. XNPT reported that it will stop development of its...